Ravi Salgia to Combined Modality Therapy
This is a "connection" page, showing publications Ravi Salgia has written about Combined Modality Therapy.
Connection Strength
0.493
-
Systemic therapies in the treatment of non-small-cell lung cancer brain metastases. Future Oncol. 2016; 12(8):1045-58.
Score: 0.105
-
EGFR-targeted therapeutics: focus on SCCHN and NSCLC. ScientificWorldJournal. 2008 Sep 21; 8:909-19.
Score: 0.063
-
A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):515-22.
Score: 0.056
-
Small cell lung cancer: from molecular biology to novel therapeutics. J Exp Ther Oncol. 2003 Nov-Dec; 3(6):305-18.
Score: 0.045
-
Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 2003 Feb 15; 21(4):624-30.
Score: 0.043
-
Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. Oncologist. 2003; 8(1):69-75.
Score: 0.042
-
RNA-based therapies: A cog in the wheel of lung cancer defense. Mol Cancer. 2021 03 19; 20(1):54.
Score: 0.037
-
Disparate outcomes in nonsmall cell lung cancer by immigration status. Cancer Med. 2021 04; 10(8):2660-2667.
Score: 0.037
-
The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States. Clin Lung Cancer. 2021 01; 22(1):e84-e97.
Score: 0.036
-
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
Score: 0.016
-
Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers. Am J Clin Oncol. 2007 Jun; 30(3):258-63.
Score: 0.014